Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

NCT02618187 is registered in ClinicalTrials.gov with Seres Therapeutics, Inc. as lead sponsor.

NCT NCT02618187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02618187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
Lead sponsor
Seres Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 13, 2016
Completion date
January 26, 2018
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis